Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in DKK (TTM)134.61bn
  • Net income in DKK46.18bn
  • Incorporated1931
  • Employees46.98k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG28.60bn3.70bn328.01bn14.41k88.956.2645.9311.476.889.5253.2597.830.2732----240,386.903.555.124.326.3541.9538.9513.0013.11--26.490.331933.197.153.4612.8321.3929.815.31
GlaxoSmithKline plc295.41bn38.23bn720.17bn94.07k18.925.2711.542.440.85360.85366.603.070.41761.694.29354,
Sanofi SA286.54bn45.96bn832.54bn99.41k18.00--14.422.914.924.9230.71--------387,237.00--4.98--5.9768.2668.1316.1214.73--29.35--69.80-0.69621.40323.6022.79-5.281.78
Novo Nordisk A/S134.61bn46.18bn1.08tn46.98k30.4620.9320.968.0219.9919.9958.2429.100.85731.254.973,009,749.0029.4135.3059.6967.1882.8984.1034.3133.510.8187--0.172250.324.043.308.183.8728.087.29
AstraZeneca plc215.72bn9.67bn1.15tn76.10k88.954.3926.725.320.93970.939717.8719.030.38311.334.71319,777.001.713.882.315.4671.2080.974.4710.190.68352.410.4443141.039.161.50139.402.50-1.340.2156
Data as of Jan 25 2022. Currency figures normalised to Novo Nordisk A/S's reporting currency: Danish Krone DKK

Institutional shareholders

13.45%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 202043.50m2.45%
The Vanguard Group, Inc.as of 06 Jan 202242.57m2.40%
BlackRock Fund Advisorsas of 06 Jan 202227.57m1.56%
Alecta Pension Insurance Mutualas of 31 Dec 201927.09m1.53%
Capital Research & Management Co. (World Investors)as of 31 Dec 202121.70m1.22%
Fundsmith LLPas of 30 Jun 202120.53m1.16%
BlackRock Investment Management (UK) Ltd.as of 06 Jan 202220.19m1.14%
Handelsbanken Fonder ABas of 31 Dec 202112.29m0.69%
BlackRock Advisors (UK) Ltd.as of 06 Jan 202211.98m0.68%
Allianz Global Investors GmbHas of 20 Jan 202210.99m0.62%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.